Altimmune adds 48-week IMPACT data for pemvidutide in MASH: full analysis
Altimmune used EASL 2026 to add more detail to the pemvidutide story in MASH, reporting fresh 48-week IMPACT Phase 2b data that it says show meaningful improvements not just in liver-related measures, but also in lipids, weight, BMI, waist circumference, and blood pressure. The presentation was selected for “Best of EASL 2026,” and the company is positioning the findings as support for a broader cardiometabolic and liver benefit profile ahead of Phase 3. (ir.altimmune.com)
The background here matters. Altimmune had already disclosed 48-week topline IMPACT results in December 2025, saying pemvidutide improved key non-invasive fibrosis markers such as ELF and liver stiffness measurement versus placebo. Earlier, the ongoing multicenter, randomized, double-blind, placebo-controlled IMPACT trial had drawn attention for its 24-week dataset, and the study population was a relatively advanced one: 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, with and without diabetes, randomized to weekly pemvidutide 1.2 mg, 1.8 mg, or placebo. (ir.altimmune.com)
The newest EASL update focused on metabolic risk factors at 48 weeks. According to Altimmune, the 1.8 mg dose produced significant reductions in triglycerides of 23.7% and total cholesterol of 15.4% in patients with elevated baseline values versus placebo, alongside a 3 kg/m² reduction in BMI, a 5.3 cm drop in waist circumference, and blood pressure improvements of 4 mmHg systolic and 2.2 mmHg diastolic. The company also said patients on 1.8 mg achieved sustained 7.5% weight loss with no plateau observed by 48 weeks. In a separate May 27 analysis, Altimmune said pemvidutide also drove concurrent improvements across multiple non-invasive tests, including liver fat content, ALT, liver stiffness, and ELF, while AI-based qFibrosis analysis showed at least one-stage fibrosis regression in 68.6% of patients on 1.2 mg and 54.5% on 1.8 mg, compared with 29.6% on placebo after 24 weeks. (globenewswire.com)
Altimmune’s regulatory position has also strengthened in recent months. The company said FDA granted Breakthrough Therapy Designation for pemvidutide in MASH and that an end-of-phase 2 meeting resulted in alignment on a registrational Phase 3 trial in patients with moderate to advanced fibrosis. In its May 13 business update, Altimmune said it had about $535 million in cash, cash equivalents, and short-term investments as of April 30, 2026, following an April financing, and that it was already incurring startup costs for the planned PERFORMA Phase 3 study. Altimmune has also been advancing pemvidutide beyond MASH: the Phase 2 RECLAIM trial in alcohol use disorder is expected to report topline data in Q3 2026, and enrollment completion in the Phase 2 RESTORE trial in alcohol-associated liver disease is anticipated in Q3 2026. (ir.altimmune.com)
On outside reaction, Altimmune’s EASL materials included comments from Naim Alkhouri, chief medical officer at Summit Clinical Research, who said the ability to show concurrent improvements across multiple non-invasive markers, supported by histologic fibrosis measures, offers a more clinically meaningful picture of potential benefit in MASH. That’s still company-distributed commentary rather than an independent conference-floor critique, but it reflects the current emphasis in the field: sponsors increasingly need to show consistent signals across fibrosis, inflammation, steatosis, and metabolic risk, not just weight loss alone. That interpretation is supported by the pattern of endpoints Altimmune chose to emphasize in its EASL presentations. (globenewswire.com)
Why it matters: For veterinary professionals, this is mainly a pipeline and translational science story rather than a practice-change event. Still, it’s notable because liver disease, obesity biology, inflammation, and cardiometabolic dysfunction are increasingly studied through shared mechanistic lenses across species. Pemvidutide’s dual glucagon/GLP-1 approach is being framed as distinct from a standard incretin-only strategy, with Altimmune arguing that glucagon activity may contribute direct liver effects while GLP-1 activity supports appetite suppression and weight loss. If that profile holds up in Phase 3, it could further shape how clinicians and industry think about combination metabolic-hepatic mechanisms, biomarkers, and trial design. The company’s parallel work in alcohol use disorder and alcohol-associated liver disease also reinforces that broader liver-metabolic positioning. (globenewswire.com)
There are still important caveats. The new data were presented through company press materials and conference abstracts, not a new peer-reviewed full paper, and the fibrosis findings highlighted this week include exploratory imaging and digital pathology analyses. ClinicalTrials.gov also indicates that, as of the latest listing, no study results had been posted there for IMPACT. So while the dataset appears to be maturing in a favorable direction, the next real test will be whether the Phase 3 design can convert these biomarker and metabolic signals into a registrational package regulators will accept. (clinicaltrials.gov)
What to watch: Altimmune says PERFORMA, its Phase 3 MASH trial, is slated to begin in the second half of 2026, making trial initiation, enrollment details, endpoint design, and any additional peer-reviewed data the next key milestones. Also worth watching are Q3 2026 topline data from RECLAIM in alcohol use disorder and Q3 2026 enrollment completion for RESTORE in alcohol-associated liver disease. (globenewswire.com)